Stock Screener App

Frei -

Installieren

45.38

0.34% -0.105

Alkermes Plc (ALKS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ALKS? Forum Prognose Aktiensplit

Alkermes Plc Aktie (ALKS) Neueste Nachrichten

After two decades at Alkermes, a biotech CFO joins Tortugas’ board - Stock Titan

Responsive Playbooks and the ALKS Inflection - Stock Traders Daily

Alkermes Plc (ALKS) Investor Outlook: Strong Buy Ratings And 21% Potential Upside - DirectorsTalk Interviews

Should Alkermes’ (ALKS) Narcolepsy Data And Phase 3 Pivot Reshape Investor Views On Its Pipeline? - simplywall.st

Alkermes (ALKS) EVP and CLO David Gaffin Sells 2,034 Shares - GuruFocus

Alkermes (NASDAQ: ALKS) officer readies stock sale - Stock Titan

Alkermes (NASDAQ: ALKS) exec lines up $423K stock sale - Stock Titan

ALKS News | ALKERMES PLC (NASDAQ:ALKS) - ChartMill

Mizuho reiterates Alkermes stock rating ahead of ADHD trial data By Investing.com - Investing.com South Africa

Mizuho reiterates Alkermes stock rating ahead of ADHD trial data - Investing.com

Alkermes plc (ALKS) Stock Analysis: Exploring an 18% Potential Upside with a Solid Revenue Growth Story - DirectorsTalk Interviews

Discipline and Rules-Based Execution in ALKS Response - Stock Traders Daily

Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000 - The Globe and Mail

Alkermes PLC (ALKS) Stock Down 3.1% but Still Overvalued -- GF S - GuruFocus

Rising Star: Goodwin's Heath Ingram - Law360

ALKS Looks 52.4% Overvalued on GF Value™ Amid New Drug Pricing D - GuruFocus

Alkermes narcolepsy drug shows positive phase 2 trial results By Investing.com - Investing.com Nigeria

Alkermes narcolepsy drug shows positive phase 2 trial results - Investing.com

Alkermes PLC (ALKS) Shares Fall 4.4% -- What GF Score of 64 Tells Investors - GuruFocus

Alkermes ends Amneal VIVITROL supply pact without penalties - scanx.trade

Alkermes reports phase 2 Vibrance-2 data; alixorexton meets dual primary endpoints in narcolepsy type 2 - scanx.trade

Alkermes (ALKS) Shares: Posts a 3.31% Loss to $48.52 for the Current Session; Current Setup: Traders Can Monitor the $46.09-$50.95 Range for the Current SessionStatistical Arbitrage - vinanet.vn

Q2 2026 Alkermes Plc Earnings Call Transcript - GuruFocus

Empowered Funds LLC Sells 53,381 Shares of Alkermes plc $ALKS - MarketBeat

STU:8AK EV-to-OCF: 37.38 — 44% Above Median - GuruFocus

Alkermes (ALKS) SVP, Chief Commercial Officer Christian Nichols Sells 7,576 Shares - GuruFocus

Alkermes (NASDAQ:ALKS) SVP Sells $372,966.48 in Stock - MarketBeat

Alkermes (NASDAQ: ALKS) holder to sell 7,576 shares worth $373K - Stock Titan

Alkermes (ALKS) Advances 1.53% as Shares Hold Firm Above Key SupportVOLD Alert - Vinanet

Alkermes Plc (ALKS) Stock Analysis: A Look At The 14.15% Potential Upside - DirectorsTalk Interviews

Alkermes (ALKS) Eases to $49.06: Key Levels to Watch After 0.79% DipPrice Target - Vinanet

S&CO Inc. Takes Position in Alkermes plc $ALKS - MarketBeat

Alkermes PLC (ALKS) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus

ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes - Stocktwits

Alkermes plc $ALKS Stock Position Trimmed by Empowered Funds LLC - MarketBeat

Quantinno Capital Management LP Grows Holdings in Alkermes plc $ALKS - MarketBeat

Bank of America Corp DE Trims Position in Alkermes plc $ALKS - MarketBeat

ALKS Stock Rises 27% in 3 Months: Here's What You Should Know - TradingView

Alkermes Lowers Interest Rate Spreads with Amendment to Credit Agreement - Kalkine Media

Alkermes amends credit agreement to reduce interest rates on term loans - Investing.com Nigeria

Form 8K Alkermes plc. For: 12 August By Investing.com - Investing.com Canada

Alkermes Reduces Spreads on $1.52 Billion Term Loans by Up to 75 bps - TradingView

Alkermes (NASDAQ: ALKS) lowers interest spreads on large term loan A and B debt - Stock Titan

Alkermes plc Enters into Amendment to Credit Agreement Reducing Interest Rate Spread on Term Loan Facilities - marketscreener.com

Hennion & Walsh Asset Management Inc. Makes New Investment in Alkermes plc $ALKS - MarketBeat

Could Alkermes plc (ALKS) Stock Rebound After Investors Look Beyond Near-Term Profit Pressure? - Yahoo Finance

Alkermes plc (ALKS) Stock Analysis: Evaluating a 13.89% Upside in the Biopharmaceutical Sector - DirectorsTalk Interviews

Alkermes Plc (ALKS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Did Alkermes’ (ALKS) Profit Slide and Cash-Conserving Moves Just Shift Its Investment Narrative? - simplywall.st

The Manufacturers Life Insurance Company Sells 42,319 Shares of Alkermes plc $ALKS - MarketBeat

Royal Bank of Canada Sells 21,159 Shares of Alkermes plc $ALKS - MarketBeat

(ALKS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Amundi Increases Stake in Alkermes plc $ALKS - MarketBeat

Alkermes plc $ALKS Shares Acquired by California State Teachers Retirement System - MarketBeat

Sei Investments Co. Has $5.44 Million Stake in Alkermes plc $ALKS - MarketBeat

Major Decision: Nancy Snyderman Exercises Options, Realizing $116K At Alkermes - Benzinga

Alkermes Insider Sold Shares Worth $2,239,076, According to a Recent SEC Filing - marketscreener.com

Form 4 Alkermes plc. For: 3 August By Investing.com - Investing.com South Africa

Alkermes Plc (ALKS) Stock Analysis: A Compelling 14% Upside Potential For Investors - DirectorsTalk Interviews

Alkermes (ALKS) insider David Gaffin details equity-award stock sales - Stock Titan

RDY

$11.84

0.32%

ELAN

$23.77

0.81%

NBIX

$153.69

0.90%

VTRS

$16.54

0.47%

UTHR

$503.10

0.86%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters